脂肪性肝病的遗传风险:发病机制、预后及治疗启示
本文综述了20余年人类遗传学研究对脂肪性肝病(SLD)的认识,指出主要SLD相关变异均定位于肝脏脂质代谢基因,其效应与对肝脏甘油三酯水平的影响成比例,并挑战了肝脂肪变良性的旧观念。多数变异对代谢功能障碍相关SLD(MASLD)和酒精相关肝病(ALD)效果相似,提示共享致病机制。遗传效应受肥胖、胰岛素抵抗和饮酒等非遗传因素影响,GLP-1受体激动剂可能成为SLD一线治疗。
要点
- SLD遗传变异集中于肝脏脂质代谢基因,效应与甘油三酯水平影响成比例
- 肝脂肪变并非良性,遗传变异影响从脂肪变到肝细胞癌的全谱
- MASLD与ALD共享遗传致病机制,非遗传因素显著修饰遗传效应
核心结论
- SLD遗传变异集中于脂质代谢基因,效应与肝脏甘油三酯水平成比例,挑战肝脂肪变良性观念。
- 多数变异对MASLD和ALD效果相似,提示两种SLD病因共享致病机制。
- GLP-1受体激动剂预测将成为SLD一线治疗,即使在高遗传风险个体中。
研究设计与样本
- 综述总结20余年人类遗传学研究,未报告具体样本量或检索范围。
主要发现
- 所有主要SLD相关变异定位于肝脏脂质代谢基因,凸显脂质失衡在SLD发展中的基础作用。
- 几乎所有风险和保护性变异与SLD全谱相关,效应与对肝脏甘油三酯水平的影响成比例。
- 遗传变异效应受肥胖、胰岛素抵抗和饮酒等非遗传因素强烈影响。
- GLP-1受体激动剂治疗肥胖和胰岛素抵抗,预测成为SLD一线治疗。
- 遗传研究为多种靶向治疗开发铺平道路。
临床怎么用
- 临床应认识到肝脂肪变并非良性,遗传变异影响SLD全谱预后。
- MASLD和ALD共享遗传机制,评估和治疗需考虑共同通路。
- 遗传效应受肥胖等因素修饰,管理应关注非遗传风险因素。
- GLP-1受体激动剂可能成为SLD一线治疗,包括高遗传风险个体。
- 遗传研究推动靶向治疗发展,未来可能实现个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steatotic liver disease (SLD) is a leading cause of liver-related morbidity and mortality worldwide. Obesity, insulin resistance, and chronic alcohol intake are its major risk factors, but genetic differences strongly influence disease susceptibility. Human genetic studies have identified key genetic modifiers of SLD risk, thereby deepening our understanding of disease pathogenesis. All major SLD-associated variants localize to genes involved in hepatic lipid metabolism, underscoring the fundamental role of lipid imbalance in SLD development. Nearly all risk and protective variants are associated with the full spectrum of SLD-from steatosis and steatohepatitis to cirrhosis and hepatocellular carcinoma-with effects on progression proportional to their impact on hepatic triglyceride (TG) levels. These findings have challenged the earlier notion that hepatic steatosis is benign. Furthermore, most variants exert similar effects on metabolic dysfunction-associated SLD (MASLD) and alcohol-associated liver disease (ALD), pointing to shared pathogenic mechanisms of these 2 SLD etiologies. The effects of genetic variants are strongly influenced by nongenetic factors, such as obesity, insulin resistance, and alcohol intake. The advent of GLP-1 receptor agonists for treating obesity and insulin resistance has transformed the therapeutic landscape for SLD. These agents are predicted to become the first-line therapy for SLD, even among individuals at the highest genetic risk. In addition, genetic studies have paved the way for the development of several targeted therapies. Here, we review the major insights into SLD pathogenesis gleaned from over 20 years of human genetic studies, and their implications for the treatment and prevention of SLD.
引用
- Kozlitina J, Romeo S, Hobbs HH, et al. Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment. Hepatology. 2026. PMID: 41962050. doi:10.1097/HEP.0000000000001758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。